Article ID Journal Published Year Pages File Type
9194576 Journal of Neuroimmunology 2005 9 Pages PDF
Abstract
These data reveal that the GEM assay is a useful adjunct in the management of MS patients treated with IFNβ, and that lost bioactivity returns when anti-IFNβ antibody levels diminish.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies
Authors
, , , ,